Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3HP for TB prevention in people with diabetes
NCT04600167Phase 3Recruiting
- Start
- Jun 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of rifapentine, isoniazid in Tuberculosis (TB). Started Jun 2022; status: recruiting.
02
Drugs
rifapentineisoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04600167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04600167.